Boston Scientific faces class action over misleading growth claims, stock drops 17.6% after poor earnings report

Boston Scientific is under investigation for allegedly misleading investors about the sustainability of growth in its U.S. EP segment. After the company reported disappointing fourth quarter and full-year 2025 results and issued weak guidance for fiscal 2026, its stock price fell 17.6% on February 4, 2026. The lawsuit claims Boston Scientific and its executives made false statements and failed to disclose the true state of the business segment, surprising investors and analysts. Investors who bought shares between July 23, 2025, and February 3, 2026, are encouraged to contact Faruqi & Faruqi LLP to discuss their legal options before the May 4, 2026 deadline to seek lead plaintiff status.